A Look At Cybin (HELP) Valuation After Positive Phase 2 HLP004 Anxiety Data [Yahoo! Finance]
Cybin Inc. (HELP)
Company Research
Source: Yahoo! Finance
Cybin (HELP) is back in focus after Helus Pharma reported Phase 2 topline data for HLP004 in generalized anxiety disorder, showing clinically meaningful symptom reductions and durable remission in patients who had remained symptomatic on standard care. See our latest analysis for Cybin. Despite the upbeat Phase 2 readout and recent conference appearances, momentum in Cybin's share price has been weak. The 7 day share price return is 28.57% and the 1 year total shareholder return is 27.98%, suggesting sentiment around execution risk and future funding needs is still cautious. If this kind of high risk biotech story feels intense, it could be worth balancing your watchlist with 32 healthcare AI stocks , a curated set of healthcare names linked to AI that some investors use to source differentiated ideas. With Cybin trading at US$5.25 and an analyst target that is materially higher, yet multi year returns deeply negative, the key question is simple: are you looking at a misprice
Show less
Read more
Impact Snapshot
Event Time:
HELP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HELP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HELP alerts
High impacting Cybin Inc. news events
Weekly update
A roundup of the hottest topics
HELP
News
- Helus Pharma Strengthens Executive Team with Appointment of Jill Conwell as Chief People Officer [Yahoo! Finance]Yahoo! Finance
- Helus Pharma Strengthens Executive Team with Appointment of Jill Conwell as Chief People OfficerGlobeNewswire
- CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Helus Pharma Announces Topline Results in Phase 2 Signal Detection Study for HLP004 in Patients with Generalized Anxiety Disorder [Yahoo! Finance]Yahoo! Finance
- Helus Pharma Announces Topline Results in Phase 2 Signal Detection Study for HLP004 in Patients with Generalized Anxiety DisorderGlobeNewswire
HELP
Earnings
- 2/13/26 - Miss
HELP
Sec Filings
- 3/23/26 - Form D
- 3/12/26 - Form 6-K
- 3/5/26 - Form 6-K
- HELP's page on the SEC website